Clinical Trials
9
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)β’ Click on a phase to view related trials
Safety and Efficacy of KPI-121 in Subjects With DED
- Conditions
- Kerato Conjunctivitis Sicca
- Interventions
- Drug: KPI-121 Ophthalmic SuspensionDrug: Vehicle
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Kala Pharmaceuticals, Inc.
- Target Recruit Count
- 901
- Registration Number
- NCT03616899
- Locations
- πΊπΈ
Investigator #133, Birmingham, Alabama, United States
πΊπΈInvestigator #278, Dothan, Alabama, United States
πΊπΈInvestigator #146, Chandler, Arizona, United States
KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children
- Conditions
- Ocular Inflammation
- Interventions
- Drug: KPI-121 1%
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Kala Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03596723
- Locations
- πΊπΈ
Byers Eye Institute at Stanford University, Palo Alto, California, United States
πΊπΈChildren's Eye Care, PC, Detroit, Michigan, United States
πΊπΈPediatric Ophthalmology of Erie, Inc., Erie, Pennsylvania, United States
Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease
- Conditions
- Keratoconjunctivitis SiccaDry Eye Syndromes
- Interventions
- Drug: Vehicle of KPI-121 0.25% Ophthalmic SuspensionDrug: KPI-121 0.25% Ophthalmic Suspension
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Kala Pharmaceuticals, Inc.
- Target Recruit Count
- 909
- Registration Number
- NCT02819284
- Locations
- πΊπΈ
UAB School of Optometry, Birmingham, Alabama, United States
πΊπΈArizona Eye Center, Chandler, Arizona, United States
πΊπΈNEA Baptist Clinic, Jonesboro, Arkansas, United States
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
- Conditions
- Keratoconjunctivitis SiccaDry Eye Syndromes
- Interventions
- Drug: KPI-121 0.25% Ophthalmic SuspensionDrug: Vehicle of KPI-121 0.25% Ophthalmic Suspension
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Kala Pharmaceuticals, Inc.
- Target Recruit Count
- 918
- Registration Number
- NCT02813265
- Locations
- πΊπΈ
Cornea and Cataract Consultants of Arizona, Phoenix, Arizona, United States
πΊπΈSchwartz Laser Eye Center, Scottsdale, Arizona, United States
πΊπΈEyecare Arkansas, P.A., Little Rock, Arkansas, United States
Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain
- Conditions
- Post Surgical Ocular Inflammation and Pain
- Interventions
- Drug: KPI-121 1% Ophthalmic Suspension dosed BIDDrug: Vehicle of KPI-121 Ophthalmic Suspension dosed BID
- First Posted Date
- 2016-06-08
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- Kala Pharmaceuticals, Inc.
- Target Recruit Count
- 520
- Registration Number
- NCT02793817
- Locations
- πΊπΈ
Arizona Eye Center, Chandler, Arizona, United States
πΊπΈCornea and Cataract Consultants of CA, Phoenix, Arizona, United States
πΊπΈSall Research Medical Center, Artesia, California, United States
- Prev
- 1
- 2
- Next